
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Adhatoda vasica is an Ayurvedic herb containing vasicine and vasicinone alkaloids that support respiratory health through bronchodilatory and anti-inflammatory mechanisms. Clinical evidence shows it reduces inflammatory markers IL-6 and TGF-β1 while supporting recovery in mild respiratory conditions.

Origin & History

Adhatoda vasica (also known as Justicia adhatoda or Vasa) is a perennial shrub native to India, Sri Lanka, and Southeast Asia, belonging to the Acanthaceae family. The leaves are the primary medicinal source, typically prepared as whole aqueous extracts through boiling or decoction methods. The plant contains alkaloids as its main chemical class, including the bioactive compounds vasicine and vasicinone.
Research Narrative (Provisional)
A randomized open-label trial (n=136 completed) tested 500mg/day AV extract for 14 days in mild COVID-19 patients, showing reduced inflammatory markers and no disease progression (PMID: 38049897). An open-label trial demonstrated efficacy in reducing gastric acid in non-ulcer dyspepsia (PMID: 22557371). Most other evidence comes from preclinical models showing anti-inflammatory and anti-hypoxic mechanisms.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Adhatoda vasica (Malabar nut) is a medicinal shrub rather than a dietary food source; its nutritional profile centers on bioactive phytochemicals rather than conventional macronutrients. Key bioactive compounds include: Alkaloids (primary class) — Vasicine (peganine) at approximately 0.541–1.0% dry weight of leaves (the dominant alkaloid and principal active constituent), Vasicinone at ~0.07–0.15% dry weight, Vasicol, Adhatodine, Adhavasine, and Vasicinol present in trace quantities (<0.05%); Flavonoids — Quercetin, Kaempferol, Apigenin, and Vitexin detected in leaf extracts (total flavonoid content reported at approximately 12–18 mg quercetin equivalents per gram dry extract); Tannins — approximately 2–5% by dry weight; Phenolic acids — Gallic acid, caffeic acid, and ferulic acid present in measurable quantities (total phenolics ~25–40 mg gallic acid equivalents per gram dry extract); Saponins — approximately 1–3% dry weight; Essential oils — trace volatile compounds including terpinene and linalool; Sterols — β-sitosterol and stigmasterol identified chromatographically. Macronutrient data for raw leaf (limited data): crude protein ~12–15% dry weight, crude fiber ~18–22% dry weight, ash content ~8–10% dry weight. Micronutrients detected include calcium (~1,200–1,800 mg/100g dry leaf), iron (~15–25 mg/100g dry leaf), potassium (~900–1,200 mg/100g dry leaf), and zinc (~2–4 mg/100g dry leaf). Bioavailability notes: Vasicine is moderately bioavailable orally; alkaloid absorption is enhanced in aqueous decoctions compared to raw powder; co-administration with piperine has been shown in preclinical models to improve extraction efficiency. The plant is not consumed as food; therapeutic doses are derived from standardized extracts or traditional decoctions, not nutritional intake.
Reported Mechanism (Provisional)
Adhatoda vasica's primary bioactive compounds vasicine and vasicinone act as bronchodilators by relaxing smooth muscle in airways. The herb reduces pro-inflammatory cytokines IL-6 and TGF-β1 while modulating inflammation-related gene expression. Vasicine also demonstrates expectorant properties by increasing respiratory secretions and improving mucus clearance.
Clinical Narrative (Provisional)
A randomized controlled trial (n=136) in mild COVID-19 patients showed Adhatoda vasica significantly reduced inflammatory markers IL-6 and TGF-β1, with 100% recovery rates and no progression to severe disease. The study demonstrated measurable anti-inflammatory effects with reduced inflammation-related gene expression. However, clinical evidence remains limited to this single trial, requiring additional research to establish broader therapeutic applications and optimal dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







